Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q4 FY21 results · Jan–Mar 2021
Suven Life Sciences reported revenue from operations of ₹1.56 crore (down 82.0% from Q4 FY20) and net loss of ₹21.61 crore for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.56 | 8.66 | −82.0% | 1.51 | +2.9% |
| Other income | 1.32 | 3.00 | −55.9% | 1.62 | −18.5% |
| Total income | 2.88 | 11.66 | −75.3% | 3.14 | −8.2% |
| Profit before tax | (21.57) | (23.36) | Loss narrowed | (26.30) | Loss narrowed |
| Net profit for the period | (21.61) | (25.56) | Loss narrowed | (24.39) | Loss narrowed |
| EPS, basic (₹) | (1.70) | (2.01) | Loss narrowed | (1.92) | Loss narrowed |
| Net margin (%) | -1388.0 | -295.1 | -1612.2 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.56 | 8.66 | −82.0% | 1.51 | +2.9% |
| Other income | 1.32 | 3.00 | −55.9% | 1.62 | −18.5% |
| Total income | 2.88 | 11.66 | −75.3% | 3.14 | −8.2% |
| Profit before tax | (8.46) | (0.36) | Loss widened | (10.05) | Loss narrowed |
| Net profit for the period | (8.51) | (2.56) | Loss widened | (8.15) | Loss widened |
| EPS, basic (₹) | (0.67) | (0.20) | Loss widened | (0.64) | Loss widened |
| Net margin (%) | -546.4 | -29.6 | -538.5 |
Consolidated
- Filed with BSE
- 05 May 2021, 12:30 IST
- Board meeting
- 04 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 May 2021, 12:30 IST
- Board meeting
- 04 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE